NIOX Group Plc Stock

Equities

CIR

GB00BJVD3B28

Pharmaceuticals

Market Closed - London S.E. 11:35:15 2024-06-07 am EDT 5-day change 1st Jan Change
68.8 GBX -1.15% Intraday chart for NIOX Group Plc -2.55% +2.69%
Sales 2024 * 42.38M 53.91M Sales 2025 * 47.73M 60.72M Capitalization 292M 371M
Net income 2024 * 12M 15.27M Net income 2025 * 14M 17.81M EV / Sales 2024 * 6.23 x
Net cash position 2024 * 27.82M 35.4M Net cash position 2025 * 36.49M 46.42M EV / Sales 2025 * 5.35 x
P/E ratio 2024 *
25 x
P/E ratio 2025 *
21.4 x
Employees 92
Yield 2024 *
1.61%
Yield 2025 *
2.13%
Free-Float 50.26%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.15%
1 week-2.55%
Current month-2.55%
1 month-3.64%
3 months+3.30%
6 months+5.85%
Current year+2.69%
More quotes
1 week
66.91
Extreme 66.906
73.80
1 month
66.91
Extreme 66.906
75.60
Current year
57.20
Extreme 57.2
75.60
1 year
54.00
Extreme 54
75.60
3 years
27.86
Extreme 27.8614
75.60
5 years
12.50
Extreme 12.5
75.60
10 years
12.50
Extreme 12.5
356.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 59 20-01-08
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 19-09-01
Members of the board TitleAgeSince
Chairman 71 19-12-04
Director of Finance/CFO 59 20-01-08
Director/Board Member 67 20-03-01
More insiders
Date Price Change Volume
24-06-07 68.8 -1.15% 221,169
24-06-06 69.6 -0.57% 210,978
24-06-05 70 +0.29% 411,742
24-06-04 69.8 -0.57% 244,783
24-06-03 70.2 -0.57% 123,286

Delayed Quote London S.E., June 07, 2024 at 11:35 am EDT

More quotes
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.688 GBP
Average target price
0.7825 GBP
Spread / Average Target
+13.74%
Consensus

Annual profits - Rate of surprise